Update on imatinib for gastrointestinal stromal tumors: duration of treatment

References

• GattaGvan der ZwanJMCasaliPGRare cancers are not so rare: the rare cancer burden in EuropeEur J Cancer201147172493251122033323
   PubMed Web of Science ®Google Scholar
• DrukerBJTalpazMRestaDJEfficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemiaN Engl J Med2001344141031103711287972
   PubMed Web of Science ®Google Scholar
• DrukerBJTamuraSBuchdungerEEffects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cellsNat Med1996255615668616716
   PubMed Web of Science ®Google Scholar
• HeinrichMCGriffithDJDrukerBJWaitCLOttKAZiglerAJInhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitorBlood200096392593210910906
   PubMed Web of Science ®Google Scholar
• TuvesonDAWillisNAJacksTSTI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene200120365054505811526490
   PubMed Web of Science ®Google Scholar
• JoensuuHRobertsPJSarlomo-RikalaMEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorN Engl J Med2001344141052105611287975
   PubMed Web of Science ®Google Scholar
• BesmerPMurphyJEGeorgePCA new acute transforming feline retrovirus and relationship of its oncogene v-kit with the protein kinase gene familyNature198632060614154213007997
   PubMed Web of Science ®Google Scholar
• YardenYKuangWJYang-FengTHuman proto-oncogene c-kit: a new cell surface receptor tyrosine kinase for an unidentified ligandEMBO J1987611334133512448137
   PubMed Web of Science ®Google Scholar
• DiNittoJPDeshmukhGDZhangYFunction of activation loop tyrosine phosphorylation in the mechanism of c-Kit auto-activation and its implication in sunitinib resistanceJ Biochem2010147460160920147452
   PubMed Web of Science ®Google Scholar
• MolCDLimKBSridharVStructure of a c-kit product complex reveals the basis for kinase transactivationJ Biol Chem200327834314613146412824176
   PubMed Web of Science ®Google Scholar
• MolCDFabbroDHosfieldDJStructural insights into the conformational selectivity of STI-571 and related kinase inhibitorsCurr Opin Drug Discov Devel200475639648
   Google Scholar
• MolCDDouganDRSchneiderTRStructural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinaseJ Biol Chem200427930316553166315123710
   PubMed Web of Science ®Google Scholar
• LennartssonJRonnstrandLStem cell factor receptor/c-Kit: from basic science to clinical implicationsPhysiol Rev20129241619164923073628
   PubMed Web of Science ®Google Scholar
• RoskoskiRJrSignaling by Kit protein-tyrosine kinase – the stem cell factor receptorBiochem Biophys Res Commun2005337111316129412
   PubMed Web of Science ®Google Scholar
• JahnTSeipelPUrschelSPeschelCDuysterJRole for the adaptor protein Grb10 in the activation of AktMol Cell Biol200222497999111809791
   PubMed Web of Science ®Google Scholar
• van OosteromATJudsonIVerweijJSafety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a Phase I studyLancet200135892911421142311705489
   PubMed Web of Science ®Google Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• VerweijJvan OosteromABlayJYImatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group Phase II studyEur J Cancer200339142006201112957454
   PubMed Web of Science ®Google Scholar
• VerweijJCasaliPGZalcbergJProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialLancet200436494401127113415451219
   PubMed Web of Science ®Google Scholar
• BlankeCDRankinCDemetriGDPhase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033J Clin Oncol200826462663218235122
   PubMed Web of Science ®Google Scholar
• CasaliPGVerweijJKotasekDImatinib mesylate in advanced gastrointestinal stromal tumors (GIST): survival analysis of the intergroup EORTC/ISG/AGITG randomized trial in 946 patientsEur J Cancer Suppl200532201202
   Google Scholar
• Gastrointestinal Stromal Tumor Meta-Analysis Group (MetaGIST)Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patientsJ Clin Oncol20102871247125320124181
   PubMed Web of Science ®Google Scholar
• PierottiMATamboriniENegriTPriclSPilottiSTargeted therapy in GIST: in silico modeling for prediction of resistanceNat Rev Clin Oncol20118316117021364689
   PubMed Web of Science ®Google Scholar
• TamboriniEPriclSNegriTFunctional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patientsOncogene200625456140614616751810
   PubMed Web of Science ®Google Scholar
• ZalcbergJRVerweijJCasaliPGOutcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgEur J Cancer200541121751175716098458
   PubMed Web of Science ®Google Scholar
• BlankeCDDemetriGDvon MehrenMLong-term results from a randomized Phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITJ Clin Oncol200826462062518235121
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMSciotRLe CesneAKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer20064281093110316624552
   PubMed Web of Science ®Google Scholar
• JudsonIMaPPengBImatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupCancer Chemother Pharmacol200555437938615592836
   PubMed Web of Science ®Google Scholar
• DemetriGDWangYWehrleEImatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsJ Clin Oncol200927193141314719451435
   PubMed Web of Science ®Google Scholar
• EechouteKFranssonMNReynersAKA long-term prospective population pharmacokinetic study on imatinib plasma concentrations in GIST patientsClin Cancer Res201218205780578722850565
   PubMed Web of Science ®Google Scholar
• BartolovicKBalabanovSHartmannUInhibitory effect of imatinib on normal progenitor cells in vitroBlood2004103252352912969987
   PubMed Web of Science ®Google Scholar
• DrukerBJGuilhotFO’BrienSGFive-year follow-up of patients receiving imatinib for chronic myeloid leukemiaN Engl J Med2006355232408241717151364
   PubMed Web of Science ®Google Scholar
• SongMKChungJSSeolYMMean cell volume can be an early predictor for the cytogenetic response of chronic myeloid leukemia patients treated with imatinib?Leuk Res200933111459146219446878
   PubMed Web of Science ®Google Scholar
• ConstantinidouAKrikelisDOlmosDEarly assessment of MCV to predict clinical outcome in patients with advanced gastrointestinal stromal tumors (GIST) receiving imatinibJ Clin Oncol201230 SupplS10086
   Google Scholar
• Le CesneARay-CoquardIBuiBNDiscontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised Phase 3 trialLancet Oncol2010111094294920864406
   PubMed Web of Science ®Google Scholar
• PatrikidouAChabaudSRay-CoquardIInfluence of imatinib interruption and rechallenge on the residual disease in patients with advanced GIST: results of the BFR14 prospective French Sarcoma Group randomised, Phase III trialAnn Oncol20132441087109323175622
   PubMed Web of Science ®Google Scholar
• ConleyAPAraujoDLudwigJA randomized Phase II study of perifosine (P) plus imatinib for patients with imatinib-resistant gastrointestinal stromal tumor (GIST)J Clin Oncol200927Suppl 1510563
   Google Scholar
• SchoffskiPReichardtPBlayJYA Phase I-II study of everolimus (RAD001) in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumorsAnn Oncol201021101990199820507881
   PubMed Web of Science ®Google Scholar
• DemetriGDLe-CesneAvon MehrenMFinal results form a Phase III study of IPI-504 (retaspimycin hydrochloride) versus placebo in patients (pts) with gastrointestinal stromal tumors (GIST) following failure of kinase inhibitor therapiesAbstract presented at the Gastrointestinal Cancers SymposiumOrlando, FLJanuary 22–24, 2010
   Google Scholar
• WagnerAJMorganJAChughRInhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: clinical results from Phase I trialJ Clin Oncol200826Suppl 1510503
   Web of Science ®Google Scholar
• BauerSHilgerRGrabellusFPhase I trial of panobinostat (P) and imatinib (IM) in patients with treatment-refractory gastrointestinal stromal tumors (GIST)J Clin Oncol201230 Suppl10032
   Google Scholar
• RautCPPosnerMDesaiJSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitorsJ Clin Oncol200624152325233116710031
   PubMed Web of Science ®Google Scholar
• MussiCRonellenfitschUJakobJPost-imatinib surgery in advanced/metastatic GIST: is it worthwhile in all patients?Ann Oncol201021240340819628568
   PubMed Web of Science ®Google Scholar
• Al-BatranSEHartmannJTHeidelFFocal progression in patients with gastrointestinal stromal tumors after initial response to imatinib mesylate: a three-center-based study of 38 patientsGastric Cancer200710314515217922091
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• JonesRLMcCallJAdamARadiofrequency ablation is a feasible therapeutic option in the multi modality management of sarcomaEur J Surg Oncol201036547748220060679
   PubMed Web of Science ®Google Scholar
• DileoPRandhawaRVansonnenbergESafety and efficacy of percutaneous radio-frequency ablation (RFA) in patients (pts) with metastatic gastrointestinal stromal tumor (GIST) with clonal evolution of lesions refractory to imatinib mesylate (IM)J Clin Oncol200422Suppl 149024
   Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosisArch Pathol Lab Med2006130101466147817090188
   PubMed Web of Science ®Google Scholar
• FletcherCDBermanJJCorlessCDiagnosis of gastrointestinal stromal tumors: a consensus approachHum Pathol200233545946512094370
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors: pathology and prognosis at different sitesSemin Diagn Pathol2006232708317193820
   PubMed Web of Science ®Google Scholar
• GoldJSGonenMGutierrezADevelopment and validation of a prognostic nomogram for recurrence-free survival after complete surgical resection of localised primary gastrointestinal stromal tumour: a retrospective analysisLancet Oncol200910111045105219793678
   PubMed Web of Science ®Google Scholar
• JoensuuHVehtariARiihimakiJRisk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohortsLancet Oncol201213326527422153892
   PubMed Web of Science ®Google Scholar
• DematteoRPBallmanKVAntonescuCRAdjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialLancet200937396691097110419303137
   PubMed Web of Science ®Google Scholar
• JoensuuHErikssonMSundby HallKOne vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trialJAMA2012307121265127222453568
   PubMed Web of Science ®Google Scholar
• [No authors listed]Gastrointestinal stromal tumors: ESMO clinical practice guidelines for diagnosis, treatment and follow-upAnn Oncol201223Suppl 7vii49vii5522997454
   PubMed Web of Science ®Google Scholar
• CasaliPGFumagalliEGronchiAAdjuvant therapy of gastrointestinal stromal tumors (GIST)Curr Treat Options Oncol201213327728422743760
   PubMed Web of Science ®Google Scholar
• ChenJGuoTZhangLCD133 and CD44 are universally overexpressed in GIST and do not represent cancer stem cell markersGenes Chromosomes Cancer201251218619522076958
   PubMed Web of Science ®Google Scholar
• BlayJYLe CesneARay-CoquardIProspective multicentric randomized Phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJ Clin Oncol20072591107111317369574
   PubMed Web of Science ®Google Scholar
• EisenbergBLHarrisJBlankeCDPhase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665J Surg Oncol2009991424718942073
   PubMed Web of Science ®Google Scholar
• WangDZhangQBlankeCDPhase II trial of neoadjuvant/adjuvant imatinib mesylate for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumors: long-term follow-up results of Radiation Therapy Oncology Group 0132Ann Surg Oncol20121941074108022203182
   PubMed Web of Science ®Google Scholar
• DoyonCSiderisLLeblancGLeclercYEBoudreauDDubePProlonged therapy with imatinib mesylate before surgery for advanced gastrointestinal stromal tumor results of a Phase II trialInt J Surg Oncol2012201276157623316352
   PubMedGoogle Scholar
• HohenbergerPLangerCWendtnerCMNeoadjuvant treatment of locally advanced GIST: results of APOLLON, a prospective, open label Phase II study in KIT- or PDGFRA-positive tumorsJ Clin Oncol201230 Suppl10031
   Google Scholar
• ReichardtPBlayJYBoukovinasIAdjuvant therapy in primary GIST: state-of-the-artAnn Oncol201223112776278122831984
   PubMed Web of Science ®Google Scholar
• MarinDBazeosAMahonFXAdherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinibJ Clin Oncol201028142381238820385986
   PubMed Web of Science ®Google Scholar
• KerkelaRGrazetteLYacobiRCardiotoxicity of the cancer therapeutic agent imatinib mesylateNat Med200612890891616862153
   PubMed Web of Science ®Google Scholar
• BermanENicolaidesMMakiRGAltered bone and mineral metabolism in patients receiving imatinib mesylateN Engl J Med2006354192006201316687713
   PubMed Web of Science ®Google Scholar
• BermanEGirotraMChengCEffect of long term imatinib on bone in adults with chronic myelogenous leukemia and gastrointestinal stromal tumorsLeuk Res201337779079423473999
   PubMed Web of Science ®Google Scholar
• HambergPde JongFABoonstraJGvan DoornJVerweijJSleijferSNon-islet-cell tumor induced hypoglycemia in patients with advanced gastrointestinal stromal tumor possibly worsened by imatinibJ Clin Oncol20062418e30e3116782905
   PubMedGoogle Scholar
• LuxMLRubinBPBiaseTLKIT extracellular and kinase domain mutations in gastrointestinal stromal tumorsAm J Pathol2000156379179510702394
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors – definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosisVirchows Arch2001438111211213830
   PubMed Web of Science ®Google Scholar
• ConcaEMirandaCColVDAre two better than one? A novel double-mutant KIT in GIST that responds to imatinibMol Oncol3212013 [Epub ahead of print.]
   Web of Science ®Google Scholar
• RoskoskiRJrStructure and regulation of Kit protein-tyrosine kinase – the stem cell factor receptorBiochem Biophys Res Commun200533831307131516226710
   PubMed Web of Science ®Google Scholar
• ConcaENegriTGronchiAActivate and resist: L576P-KIT in GISTMol Cancer Ther2009892491249519723893
   PubMed Web of Science ®Google Scholar
• TamboriniEBonadimanLGrecoAA new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patientGastroenterology2004127129429915236194
   PubMed Web of Science ®Google Scholar
• DuensingAMedeirosFMcConartyBMechanisms of oncogenic KIT signal transduction in primary gastrointestinal stromal tumors (GISTs)Oncogene200423223999400615007386
   PubMed Web of Science ®Google Scholar
• RossiFEhlersIAgostiVOncogenic Kit signaling and therapeutic intervention in a mouse model of gastrointestinal stromal tumorProc Natl Acad Sci USA200610334128431284816908864
   PubMed Web of Science ®Google Scholar
• BairdKDavisSAntonescuCRGene expression profiling of human sarcomas: insights into sarcoma biologyCancer Res200565209226923516230383
   PubMed Web of Science ®Google Scholar
• FrancisPNamlosHMMullerCDiagnostic and prognostic gene expression signatures in 177 soft tissue sarcomas: hypoxia-induced transcription profile signifies metastatic potentialBMC Genomics200787317359542
   PubMed Web of Science ®Google Scholar
• AstolfiANanniniMPantaleoMAA molecular portrait of gastrointestinal stromal tumors: an integrative analysis of gene expression profiling and high-resolution genomic copy numberLab Invest20109091285129420548289
   PubMed Web of Science ®Google Scholar
• LiFGrowneyJBattalagineLQiuSManleyPMonahanJThe effect combining the KIT inhibitor imatinib with the PI3K inhibitor BKM120 or the dual PI3K/mTOR inhibitor BEZ235 on the proliferation of gastrointestinal stromal tumor cell linesAbstract 2239 presented at the 103rd Annual Meeting of the American Association for Cancer ResearchChicago, ILMarch 31–April 4, 2012
   Google Scholar
• FlorisGWozniakASciotRA potent combination of the novel PI3K inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawalClin Cancer Res201319362063023231951
   PubMed Web of Science ®Google Scholar
• ChangBSYangTCibasESFletcherJAAn in vitro cytologic assay for evaluation of the KIT signaling pathway in gastrointestinal stromal tumorsMod Pathol200720557958317396139
   PubMed Web of Science ®Google Scholar
• PantaleoMANicolettiGNanniCPreclinical evaluation of KIT/PDGFRA and mTOR inhibitors in gastrointestinal stromal tumors using small animal FDG PETJ Exp Clin Cancer Res20102917321192792
   PubMed Web of Science ®Google Scholar
• DuensingAJosephNEMedeirosFProtein kinase C theta (PKCtheta) expression and constitutive activation in gastrointestinal stromal tumors (GISTs)Cancer Res200464155127513115289315
   PubMed Web of Science ®Google Scholar
• OuWBZhuMJDemetriGDFletcherCDFletcherJAProtein kinase C-theta regulates KIT expression and proliferation in gastrointestinal stromal tumorsOncogene200827425624563418521081
   PubMed Web of Science ®Google Scholar
• BauerSYuLKDemetriGDFletcherJAHeat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumorCancer Res200666189153916116982758
   PubMed Web of Science ®Google Scholar
• SmythTVan LooyTCurryJEThe HSP90 inhibitor, AT13387, is effective against imatinib-sensitive and -resistant gastrointestinal stromal tumor modelsMol Cancer Ther20121181799180822714264
   PubMed Web of Science ®Google Scholar
• FlorisGDebiec-RychterMWozniakAThe heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumorsMol Cancer Ther201110101897190821825009
   PubMed Web of Science ®Google Scholar
• MuhlenbergTZhangYWagnerAJInhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsCancer Res200969176941695019706776
   PubMed Web of Science ®Google Scholar
• EdrisBWillinghamSBWeiskopfKAnti-KIT monoclonal antibody inhibits imatinib-resistant gastrointestinal stromal tumor growthProc Natl Acad Sci USA201311093501350623382202
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLBlankeCDMolecular correlates of imatinib resistance in gastrointestinal stromal tumorsJ Clin Ocol: Official Journal of the American Society of Clinical OncologyOct 102006242947644774
   PubMed Web of Science ®Google Scholar